Offers mRNA process development and cGMP manufacturing based on microbial, DNA, and RNA production and analytical capabilities. Capabilities are not necessarily equivalent across all AGC sites.
Profile review: 2026-11-05 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Offers mRNA process development and cGMP manufacturing based on microbial, DNA, and RNA production and analytical capabilities. Capabilities are not necessarily equivalent across all AGC sites.
A biologics CDMO offering analytical and formulation development. Seattle is identified as a formulation center for liquid, lyophilized, and high-concentration drug products.
Protein and cell/gene-therapy analytical development and quality testing
Integrated CRO/CDMO analytical services
Program / service
Target / indication
Representative stage
Evidence & scope
RNA / LNP service capabilities
Project-dependent / not verified · Project-dependent / not verified
Services / platform
This record does not establish human validation of the entire platform
Formulation development / contract manufacturing capabilities
Defined by the client project · Defined by the client project
Services / platform
Service pages do not establish human evidence for every project
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.
A Communications Chemistry study reports RaPiD-mAb-MS, combining plate-based preparation with direct-infusion mass spectrometry for antibody peptide mapping. The original abstract describes analysis of 96 samples in about 1.5–2 hours, routinely exceeding 95% sequence coverage, across 28 antibodies and more than 2,000 samples. The reported comparisons cover several modifications and sequence variants; broader method suitability still requires evaluation.
Moderna reported third-quarter 2026 revenue of $1.3 billion, up 29% year over year, and GAAP net income of $162 million, compared with a $200 million loss a year earlier. It raised expected full-year revenue growth to 15%–25% from up to 10%. The company attributed quarterly growth mainly to international COVID vaccine sales supported by government partnerships.
Service scope and candidates reflect the cited disclosures. Project pricing, turnaround time, available capacity, and technology licensing terms require further confirmation.
Available capacity, site-specific qualifications, project delivery history, pricing, and technology transfer terms require confirmation with the execution entity.
Company service pages support the stated scope but do not establish clinical validation of every dosage form or client program.
Service-provider record; no proprietary drug pipeline implied. Confirm laboratory qualification and project suitability.
